OSLO, July 31st, 2023: EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage precision health company utilising Acoustic Cluster
Therapy (ACT®) across multiple therapeutic areas, today announces that the
United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has
awarded all necessary approvals to start the dose expansion part of the ACTIVATE
study.  

 

This part of the ACTIVATE study is designed to determine the dose level for
further development and expand the safety and efficacy data of ACT in patients
with metastatic colorectal cancer. 12 to 20 patients are planned to be enrolled
into the dose expansion part of the ACTIVATE study.  

 

For more information, please contact:  

Per Walday  
CEO EXACT Therapeutics  
Email: per.walday@exact-tx.com  

 

About EXACT-Tx:  

EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com  

 

About ACT®  

o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.  

o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.  

o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes. 

 

Forward looking statements: This announcement and any materials distributed in
connection with this announcement may contain certain forward-looking
statements. By their nature, forward-looking statements involve risk and
uncertainty because they reflect the Company's current expectations and
assumptions as to future events and circumstances that may not prove accurate. A
number of material factors could cause actual results and developments to differ
materially from those expressed or implied by this forward-looking statement.